Daniel P. O'Day's most recent trade in Gilead Sciences, Inc. was a trade of 10,000 Common Stock done at an average price of $113.6 . Disclosure was reported to the exchange on Aug. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 113.63 per share. | 28 Aug 2025 | 10,000 | 595,725 (0%) | 0% | 113.6 | 1,136,300 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 114.09 per share. | 28 Jul 2025 | 8,345 | 605,725 (0%) | 0% | 114.1 | 952,077 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 113.17 per share. | 28 Jul 2025 | 1,655 | 614,070 (0%) | 0% | 113.2 | 187,293 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 110.40 per share. | 30 Jun 2025 | 9,400 | 616,325 (0%) | 0% | 110.4 | 1,037,796 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 111.15 per share. | 30 Jun 2025 | 600 | 615,725 (0%) | 0% | 111.1 | 66,688 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 10,425 | 108,923 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 10,425 | 630,693 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.09 per share. | 10 Jun 2025 | 4,968 | 625,725 (0%) | 0% | 110.1 | 546,927 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 110.11 per share. | 30 May 2025 | 6,416 | 623,852 (0%) | 0% | 110.1 | 706,497 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 110.96 per share. | 30 May 2025 | 3,584 | 620,268 (0%) | 0% | 111.0 | 397,696 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 169,690 | 169,690 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 38,395 | 119,348 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 24,024 | 80,953 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 24,024 | 641,900 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.21 per share. | 10 Mar 2025 | 11,632 | 630,268 (0%) | 0% | 117.2 | 1,363,387 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 164,473 | 726,032 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.99 per share. | 04 Feb 2025 | 108,156 | 617,876 (0%) | 0% | 98.0 | 10,598,206 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 60,031 | 561,559 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 10,295 | 506,290 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 10,295 | 104,977 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.34 per share. | 10 Dec 2024 | 4,762 | 501,528 (0%) | 0% | 92.3 | 439,723 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,295 | 500,744 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,295 | 115,272 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.44 per share. | 10 Sep 2024 | 4,749 | 495,995 (0%) | 0% | 81.4 | 386,759 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 10,295 | 125,567 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 10,295 | 495,142 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.25 per share. | 10 Jun 2024 | 4,693 | 490,449 (0%) | 0% | 65.2 | 306,218 | Common Stock |